BAP1 and nonpapillary renal cell carcinoma: Consistently, BAP1 and/or SETD2 mutations were highly enriched in ccRCC-TT patients (40% vs. 8%, Fisher’s exact test, p = 0.04379), which was in agreement with a previous study24 (Supplementary Fig.  4).